Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
European journal of cancer (Oxford, England : 1990).
Times cited: 25
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America. 2004 Academic Article GET IT